Nimenrix

Active immunisation of individuals from 6 wk against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 & Y.

IM Adult, adolescent & childn ≥12 mth Primary immunisation: Administer 0.5 mL single dose. Unvaccinated infant from 6 mth to <12 mth Primary immunisation: Administer 0.5 mL single dose. Booster: At 12 mth, administer w/ min interval of at least 2 mth after primary dose. Infant from 6 wk to <6 mth Primary immunisation: Administer 2 doses (0.5 mL/dose) w/ 1st dose given from 6 wk w/ 2-mth dose interval. Booster: Administer at 12 mth. Previously vaccinated adult, adolescent & childn ≥12 mth May be given as a booster dose to individuals who have previously received primary vaccination w/ conjugated or plain polysaccharide meningococcal vaccine. Individual w/ underlying predisposing conditions to meningococcal infection due to anatomic/functional asplenia (eg, sickle cell disease) At least 1 dose may be given.

Hypersensitivity.

Appropriate medical treatment & supervision should be available in case of rare anaphylactic event following vaccination. Do not administer intravascularly, intradermally or SC. Review patient's medical history (especially previous vaccination) & clinical exam. Postpone vaccination in patients w/ acute severe febrile illness. Syncope can occur following or before any vaccination; place procedures to avoid injury from faints. Individuals w/ thrombocytopenia or any coagulation disorder. Increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 & Y in persons w/ certain complement deficiencies & those receiving treatment that inhibits terminal complement activation (eg, eculizumab) even if they develop Ab following vaccination w/ Nimenrix. Patients receiving immunosuppressive treatment or those w/ immunodeficiency may not elicit an adequate immune response. Individuals w/ increased susceptibility to meningococcal infection due to anatomic/functional asplenia (eg, sickle cell disease). No protection against other Neisseria meningitidis groups. Protective immune response may not be elicited in all vaccinees. Consider booster dose if an individual is expected to be at particular risk of exposure to group A & has previously received a dose approx >1 yr; individuals remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 & Y. Not a substitute for tetanus immunisation. Pregnancy & lactation. Consider 2nd primary dose after 2-mth interval if infant (6 to <12 mth) or toddler is expected to be at immediate risk of invasive meningococcal disease due to exposure to groups W-135 &/or Y.

Appetite loss; irritability; drowsiness, headache; fever, inj site swelling, pain & redness, fatigue. GI symptoms (including diarrhoea, vomiting & nausea); inj site haematoma.

Co-administer w/ tetanus toxoid (TT) containing vaccine (eg, DTaP/IPV/Hib/HepB vaccine) or administer Nimenrix at least 1 mth before the TT-containing vaccine. Administer at different inj sites if to be given at the same time w/ another inj vaccine. May not elicit adequate response in patients receiving immunosuppressive treatment.

Vaccines, Antisera & Immunologicals

J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.

POM